Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025)
Vireo Growth's (VREOF) quarterly Liabilities from Discontinued Operations came in at 89334872.0 in Q3 2025, up 1.02% year-on-year from 88437021.0 in Q3 2024, and little changed quarter-over-quarter from 89379390.0 in Q2 2025.
Vireo Growth (VREOF) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Vireo Growth has disclosed Liabilities from Discontinued Operations across 6 years of filings, most recently posting 89334872.0 for Q3 2025.
- Liabilities from Discontinued Operations for Q3 2025 came in at 89334872.0, up 1.02% year-over-year; the trailing twelve-month figure through Sep 2025 was 89334872.0 (up 1.02% YoY), and the FY2024 annual result was 89387203.0, up 1.2% from the prior year.
- Liabilities from Discontinued Operations came in at 89334872.0 for Q3 2025 at Vireo Growth, roughly flat from 89379390.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 89387203.0 in Q4 2024 to a low of 116803.0 in Q3 2021.
- The 5-year median for Liabilities from Discontinued Operations is 81925789.0 (2023), against an average of 58887381.31.
- Across the five-year window, Liabilities from Discontinued Operations jumped 6592.16% in 2023 and advanced 1.02% in 2025, its largest moves.
- Vireo Growth's Liabilities from Discontinued Operations stood at 116803.0 in 2021, then surged by 1029.98% to 1319847.0 in 2022, then surged by 6592.16% to 88326323.0 in 2023, then increased by 1.2% to 89387203.0 in 2024, then decreased by 0.06% to 89334872.0 in 2025.
- The last three Liabilities from Discontinued Operations figures came in at 89334872.0 (Q3 2025), 89379390.0 (Q2 2025), and 89351157.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 89.33 Mn |
| Sep 30, 2025 | 89.33 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Jun 30, 2025 | 89.38 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Mar 31, 2025 | 89.35 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Dec 31, 2024 | 89.39 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Sep 30, 2024 | 88.44 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Jun 30, 2024 | 88.41 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Mar 31, 2024 | 88.37 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Sep 30, 2023 | 75.44 Mn |
| Jun 30, 2023 | 75.15 Mn |
| Jun 30, 2023 | 75.15 Mn |